This is the main content area
19-05-2017 Brodalumab, a novel biologic for people with moderate-to-severe psoriasis, receives positive opinion from European CHMP
03-03-2017 LEO Pharma announces positive results from phase 2b clinical study for tralokinumab in atopic dermatitis.
11-10-2016 LEO Pharma announces restructuring plans to streamline its organisation and support new portfolio
30-09-2016 LEO Pharma announces collaboration with Washington University to enhance understanding of atopic dermatitis
13-09-2016 LEO Pharma strengthens global leadership to accelerate entry into biologics in dermatology
15-08-2016 LEO Pharma Research Foundation awards two promising and talented scientists in skin research
24-06-2016 LEO Pharma strengthens Board of Directors